Bio-Techne Corporation
TECH
Rang in Aktien
#1874
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Aktienkurs
$72.55
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$11.38B
Veränderung (1 Tag)
0.03%
Veränderung (1 Jahr)
17.27%
Land
US
Handel Bio-Techne Corporation (TECH)
Kategorie
Healthcare
Operative Marge für Bio-Techne Corporation (TECH)
Operative Marge zum October 2026 TTM: 20.73%
Laut den neuesten Finanzberichten und dem Aktienkurs von Bio-Techne Corporation beträgt die aktuelle operative Marge (TTM) 20.73%. Am Ende des Jahres 2024 lag die operative Marge bei 17.83%.
Historie der operativen Marge von Bio-Techne Corporation von 2000 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 20.73% | 147.37% |
| 2025 | 8.38% | -53.00% |
| 2024 | 17.83% | -32.21% |
| 2023 | 26.30% | -1.98% |
| 2022 | 26.83% | 67.06% |
| 2021 | 16.06% | 58.85% |
| 2020 | 10.11% | -42.52% |
| 2019 | 17.59% | -16.95% |
| 2018 | 21.18% | -2.08% |
| 2017 | 21.63% | -28.33% |
| 2016 | 30.18% | -7.17% |
| 2015 | 32.51% | -27.19% |
| 2014 | 44.65% | -12.49% |
| 2013 | 51.02% | -3.44% |
| 2012 | 52.84% | -6.03% |
| 2011 | 56.23% | -3.22% |
| 2010 | 58.10% | 1.72% |
| 2009 | 57.12% | 1.91% |
| 2008 | 56.05% | 0.90% |
| 2007 | 55.55% | 3.73% |
| 2006 | 53.55% | -2.14% |
| 2005 | 54.72% | 7.25% |
| 2004 | 51.02% | 9.25% |
| 2003 | 46.70% | 15.74% |
| 2002 | 40.35% | 1.61% |
| 2001 | 39.71% | 4.80% |
| 2000 | 37.89% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 38.59% | -98.14% |
US
|
|
| -149.01% | -107.19% |
US
|
|
| 25.57% | -98.77% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.61% |
NL
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.